Table of Contents
ISRN Oncology
Volume 2011 (2011), Article ID 405656, 7 pages
http://dx.doi.org/10.5402/2011/405656
Research Article

Cytotoxic Activity of Peripheral Blood Mononuclear Leukocytes, Activated by Interleukin-2/β-Cyclodextrin Nanocomposition against Androgen Receptor-Negative Prostate Cancers

1N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoe Shosse, 24, Moscow 115478, Russia
2Chemical Diversity Research Institute, Rabochaya Street 2a, Khimki, Moscow 141401, Russia
3N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, Moscow 119991, Russia
4Family Medicine Area, ASL1 Legnano and “Metabloc Cancer Center, ” c/o Centro Medico Kines, Castano Primo, 20022 Milan, Italy

Received 3 May 2011; Accepted 17 June 2011

Academic Editor: T.-C. Hour

Copyright © 2011 Natalia Yu. Anisimova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Marugame and S. Mizuno, “Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000),” Japanese Journal of Clinical Oncology, vol. 35, no. 11, pp. 690–691, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. F. Eliason, “Pegylated cytokines: potential application in immunotherapy of cancer,” BioDrugs, vol. 15, no. 11, pp. 705–711, 2001. View at Google Scholar · View at Scopus
  4. N. Stern-Ginossar, S. Nedvetzki, G. Markel et al., “Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells,” Journal of Immunology, vol. 179, no. 7, pp. 4424–4434, 2007. View at Google Scholar · View at Scopus
  5. A. W. Hsing, L. Tsao, and S. S. Devesa, “International trends and patterns of prostate cancer incidence and mortality,” International Journal of Cancer, vol. 85, no. 1, pp. 60–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. M. L. Slooten, R. Kircheis, F. J. Koppenhagen, E. Wagner, and G. Storm, “Liposomes as cytokine-supplement in tumor cell-based vaccines,” International Journal of Pharmaceutics, vol. 183, no. 1, pp. 33–36, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Negrier, A. Mercatello, M. Bret et al., “Intensive regimen of cytokines with interleukin-2 and interferon alfa-2b in selected patients with metastatic renal carcinoma,” Journal of Immunotherapy, vol. 17, no. 1, pp. 62–68, 1995. View at Google Scholar
  8. P. A. Burch, G. A. Croghan, D. A. Gastineau et al., “Immunotherapy (APC8015, provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial,” Prostate, vol. 60, no. 3, pp. 197–204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Bilensoy and H. A. Atilla, “Cyclodextrin—based nanomaterials in pharmaceutical field,” in Pharmaceutical Manufacturing Handbook: Production and Processes, S. C. Gad, Ed., pp. 1225–1248, John Wiley & Sons, Hoboken, NJ, USA, 2008. View at Google Scholar
  10. F. Quaglia, L. Ostacolo, A. Mazzaglia, V. Villari, D. Zaccaria, and M. T. Sciortino, “The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs,” Biomaterials, vol. 30, no. 3, pp. 374–382, 2009. View at Publisher · View at Google Scholar
  11. J. P. Eder, P. W. Kantoff, K. Roper et al., “Trial of a recombinant vaccinia virus expressing prostate- specific antigen in advanced prostate cancer,” Clinical Cancer Research, vol. 6, no. 5, pp. 1632–1638, 2000. View at Google Scholar · View at Scopus
  12. B. Lurri, T. Cerchiara, F. Bigucci, D. Caponio, and V. Zecchi, “Bovine serum albumin nanospheres carrying progesterone inclusion complexes,” Drug Delivery, vol. 12, no. 5, pp. 281–287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. C. Olson, W. D. W. Heston, and A. K. Rajasekaran, “Clinical trials of cancer therapies targeting prostate-specific membrane antigen,” Reviews on Recent Clinical Trials, vol. 2, no. 3, pp. 182–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Maestrelli, M. Garcia-Fuentes, P. Mura, and M. J. Alonso, “A new drug nanocarrier consisting of chitosan and hydoxypropylcyclodextrin,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 69, no. 2, pp. 79–86, 2006. View at Publisher · View at Google Scholar
  15. P. M. Arlen, M. Mohebtash, R. A. Madan, and J. L. Gulley, “Promising novel immunotherapies and combinations for prostate cancer,” Future Oncology, vol. 5, no. 2, pp. 187–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Kuroki, H. Ochiai, M. Kurokawa et al., “Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde,” Journal of Cancer Research and Clinical Oncology, vol. 117, no. 2, pp. 109–114, 1991. View at Google Scholar
  17. F. Dieli, N. Caccamo, and S. Meraviglia, “Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more,” Current Opinion in Investigational Drugs, vol. 9, no. 10, pp. 1089–1094, 2008. View at Google Scholar · View at Scopus
  18. S. Koido, E. Hara, S. Homma, K. Fujise, J. Gong, and H. Tajiri, “Dendritic/tumor fusion cell-based vaccination against cancer,” Archivum Immunologiae et Therapiae Experimentalis, vol. 55, no. 5, pp. 281–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. G. McNeel, “Prostate cancer immunotherapy,” Current Opinion in Urology, vol. 17, no. 3, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Sousa-Canavez, F. C. Canavez, K. R. M. Leite, and L. H. Camara-Lopes, “Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer,” Genetic Vaccines and Therapy, vol. 18, no. 6, article 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Fischer, B. Müller, K. G. Fischer, N. Baur, and W. Kreutz, “Acidic pH inhibits non-MHC-restricted killer cell functions,” Clinical Immunology, vol. 96, no. 3, pp. 252–263, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Frost, C. P. Ng, A. Belldegrun, and B. Bonavida, “Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity,” Cellular Immunology, vol. 180, no. 1, pp. 70–83, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Haridas and R. K. Saxena, “Correlation of class I MHC antigen levels on some human tumor cell lines with susceptibility to LAK cells and performance in cold target inhibition assays,” Cellular Immunology, vol. 161, no. 2, pp. 256–261, 1995. View at Publisher · View at Google Scholar · View at Scopus